tradmap

SLDB Solid Biosciences Inc.

$8.40 +14.91%

Healthcare · Biological Products, (No Diagnostic Substances)

Solid Biosciences Inc. (SLDB) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $827 million. Shares last traded at $8.40, 5.1% below their 52-week high. Over the past year the stock is up 76.8%. Net profit margin is -2153.8%, below the peer median of 6.3%. Revenue declined 40.6% year over year.

Market Cap
$827M
Shares Out
98.4M
EPS (TTM)
$-3.55
P/E Ratio
P/S Ratio
102.17
P/B Ratio
2.21
Dividend / Share
Dividend Yield
52-Week High
$8.85
52-Week Low
$3.79
Volume
415,958
Avg Vol (3m)
69,599.825

Performance

1W
+15.86%
1M
+37.93%
3M
+17.98%
6M
+44.08%
YTD
+53.28%
1Y
+76.84%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
64.30
SMA (50)
$7.35
SMA (200)
$6.28
Price vs SMA50
+14.22%
Price vs SMA200
+33.76%
ATR (14)
$0.53

Financials

Revenue
$8M
Net Income
$-174M
Gross Margin
Operating Margin
-2214.1%
Net Margin
-2153.8%
Return on Equity
-46.6%
Return on Assets
-41.2%
Current Ratio
13.10
Debt / Equity
0.13
Revenue Growth (YoY)
-40.6%

Latest reported annual period ending 2022-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.52 2026-05-12
FY 2025 $-1.99 2026-03-19
Q3 2025 $-1.46 2025-11-03
Q2 2025 $-0.98 2025-08-12
Q1 2026 $-0.59 2026-05-12
FY 2025 $-3.06 2026-03-19

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

SLDB vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
102.17 / 5.21 med
+1860% premium
Net margin vs peers
-2153.8% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.